Gastroenterology
Digestive system clinical trials
Conditions of the stomach, intestines, liver, and the rest of the digestive tract. We’re tracking 7,890 recruiting studies in this area right now.
By phase
- Not applicable4,918
- Phase 21,185
- Phase 1582
- Phase 3465
- Phase 1/Phase 2393
- Phase 4236
- Phase 2/Phase 3111
Top conditions
- Colorectal Cancer491
- Gastric Cancer296
- Pancreatic Cancer290
- Hepatocellular Carcinoma283
- Esophageal Cancer191
- Rectal Cancer176
- Breast Cancer146
- Crohn Disease144
- Ulcerative Colitis141
- Colon Cancer115
- Inflammatory Bowel Diseases108
- Hepatocellular Carcinoma (HCC)106
- Liver Cancer100
- Lung Cancer97
- Pancreas Cancer94
- Esophageal Squamous Cell Carcinoma88
- Ovarian Cancer88
- Cystic Fibrosis78
Leading sponsors
- Fudan University104
- Sun Yat-sen University90
- Mayo Clinic75
- Chinese University of Hong Kong60
- M.D. Anderson Cancer Center58
- Second Affiliated Hospital, School of Medicine, Zhejiang University57
- Assistance Publique - Hôpitaux de Paris55
- Sixth Affiliated Hospital, Sun Yat-sen University50
- National Taiwan University Hospital49
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences48
Where studies are running
- California461
- Arizona177
- Texas149
- Florida133
- Massachusetts128
- New York123
- Alabama122
- Maryland86
- Ohio80
- Pennsylvania72
Recruiting studies7,890 total
- NCT05965531RecruitingPhase 2
TAS-102 plus radiation before surgery for rectal cancer
This trial studies whether adding TAS-102 (a chemotherapy medicine) to radiation given before treatment improves outcomes for certain locally advanced rectal cancers. It may help by trying to shrink the tumor before the next steps of care.
Guangzhou, GuangdongAges 18–70 - NCT05967910Recruiting
How stress affects immunotherapy for esophageal cancer
This study looks at whether chronic stress changes how well immunotherapy (ICI therapy) works in people with esophageal cancer. It may help doctors understand who benefits most from treatment and how stress could affect outcomes.
Changsha, HunanAges 18–75 - NCT05968573Recruiting
Health messages intervention for people at risk of HIV or HCV
This study tests whether persuasive, health-message coaching can help people reduce risk for HIV or hepatitis C (HCV). You may be eligible if you’re not infected with HIV or HCV and haven’t been tested for either in the last year.
New York, New YorkAges 18 years+ - NCT05969041RecruitingPhase 1
Early-phase drug trial for advanced epithelial cancers
This Phase 1 study tests a new drug (MT-302) in adults with advanced or metastatic epithelial cancers that have worsened or stopped responding to standard treatment. The goal is to see how the drug works and whether it is safe for people with limited options.
Darlinghurst, New South WalesAges 18 years+ - NCT05970302RecruitingPhase 2
XELOX, bevacizumab, and immunotherapy for metastatic colon cancer
This Phase 2 trial studies a combination treatment (XELOX plus bevacizumab plus an immunotherapy drug) for people with metastatic colon cancer that has certain lab features (MSS/pMMR and RAS-mutated). It aims to see how well the treatment works as a first treatment when the cancer cannot be removed with surgery.
BeijingAges 18 years+ - NCT05970133Recruiting
Robotic surgery vs laparoscopy for left colon cancer
This trial compares two ways to remove left-sided colon cancer and take the specimen out through the anus (without a large external incision). It may help find which approach is safer and more effective for curing Stage I–III disease.
TaipeiAges 18 years+ - NCT05970666RecruitingPhase 2
TACE plus immunotherapy and VEGF drug for unresectable liver cancer
This trial tests whether combining TACE (a liver-targeted chemo procedure) with two medicines—an immune “checkpoint” drug and a blood-vessel blocking drug—can control unresectable hepatocellular carcinoma. It’s designed for people who can’t have surgery or curative ablation, and who still have reasonably strong liver and overall health.
Xiamen, FujianAges 18–75 - NCT05970705RecruitingPhase 2
Regorafenib plus TAS-102 versus regorafenib alone for advanced bowel cancer
This Phase 2 study tests whether adding TAS-102 to regorafenib works better than regorafenib by itself for metastatic colorectal cancer after at least one prior treatment has stopped working. It aims to improve how long the cancer can be controlled for patients in later treatment lines.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05971108Recruiting
Check a blood test system to catch liver cancer early
This study will test a real-world blood testing system (Elecsys GAAD) to improve surveillance and earlier detection of liver cancer in people who already have liver scarring (cirrhosis). If it works well, it could help find liver cancer sooner and potentially improve outcomes.
Manchester, Greater ManchesterAges 18 years+ - NCT05972317Recruiting
Study gut bacteria in IBS patients with and without treatment
This study looks at stool (poop) samples to understand differences in gut bacteria in people with irritable bowel syndrome (IBS), depending on whether they’ve had treatment. It may help researchers find better ways to explain IBS and improve care.
RehovotAges 18–70 - NCT05973500Recruiting
Mediterranean diet study for inflammatory bowel disease
This trial studies whether eating a Mediterranean-style diet can improve inflammatory bowel disease (including mild to moderate Crohn’s). It may help by testing changes in gut inflammation measured by your symptoms and stool tests.
San Diego, CaliforniaAges 18 years+ - NCT05974280Recruiting
Stem cell treatment for complex anal fistulas
This trial compares two types of stem cell treatments to help heal complex anal fistulas (abnormal tunnels near the anus). You may be eligible if your Crohn’s-related disease is mostly controlled and the fistula has not fully healed with standard treatments.
Nantes, NantesAges 18 years+ - NCT05974358Recruiting
Compare two bowel-connection methods to prevent Crohn’s flare-ups
This trial tests whether a specific type of bowel connection during Crohn’s surgery can lower the chances that the disease comes back. It may help people having their first ileocolonic (small-to-large bowel) surgery for certain Crohn’s complications.
BesançonAges 18–75 - NCT05974904Recruiting
Study links a liver-related cell marker to fatty liver damage
This study looks at existing health survey data to see whether a specific immune-cell marker (called HsCAR) is related to fatty liver disease and liver scarring. It may help researchers better understand which people are at higher risk for worsening liver damage.
Chongqing, Chongqing MunicipalityAges 18–90 - NCT05974722Recruiting
Compare two ways to repair large hiatal hernias
This study compares two surgical materials (mesh vs pledgets) used to repair a large hiatal hernia, helping doctors find which approach works best over time. You may be able to join if you have a specific type and size of hiatal hernia and can attend long-term follow-up visits and surveys.
Cleveland, OhioAges 18 years+ - NCT05975593Recruiting
Study how radiation affects tumor biology in cervical or pancreatic cancer
This study looks at how radiotherapy changes the tumor environment, using lab samples collected during treatment. It may help researchers understand why radiation works differently for different people and could improve future treatment planning.
St Louis, MissouriAges 18 years+ - NCT05975749RecruitingPhase 2
Trastuzumab, serplulimab, and chemo after stomach cancer surgery
This Phase 2 study looks at whether adding serplulimab to trastuzumab and chemotherapy after surgery can lower the chance of stomach cancer coming back. It is for people with HER2-positive stage II–III stomach adenocarcinoma who have already had curative surgery with lymph node removal.
Shanghai, Shanghai MunicipalityAges 20–80 - NCT05976165Recruiting
Breath testing study for small bowel bacterial overgrowth
This study checks whether breath tests can help identify small intestinal bacterial overgrowth in people with reflux-like symptoms (heartburn or regurgitation). If you qualify, you may be asked to avoid certain medicines and treatments for a short time so the test results are accurate.
Jacksonville, FloridaAges 18 years+ - NCT05977283Recruiting
Follow-up study for people whose hepatitis B test improved
This study follows people with hepatitis B (HBV) blood tests that have improved over the last year. It aims to learn what happens after the hepatitis B surface antigen (HBsAg) goes down, and may help doctors better predict outcomes.
Guangzhou, GuangdongAges 18–65 - NCT05978193RecruitingPhase 2
Radiation plus chemo-immunotherapy for advanced esophageal cancer
This trial tests whether adding radiation to a combination of chemotherapy and immunotherapy can help people with stage IV esophageal cancer that has spread. It is for those who haven't had any prior treatment for their cancer.
ShanghaiAges 18 years+ - NCT05979389RecruitingPhase 1
Bicalutamide for young women with PCOS and fatty liver
This trial tests a medicine called bicalutamide (an anti-androgen) to see if it can help young women with both PCOS and fatty liver disease (NASH). The goal is to find a new treatment option for these two conditions together.
San Francisco, CaliforniaAges 18–42 - NCT05980455Recruiting
Nighttime cycling of Enterra pacemaker for gastroparesis
This study tests a new way to program the Enterra stomach pacemaker so it cycles at night, aiming to improve gastroparesis symptoms. It's for people who already have the device and have stable symptoms.
Louisville, KentuckyAges 18–70 - NCT05981300Recruiting
Pediatric Gastroparesis Research Registry
This study collects information from children and young adults with gastroparesis (a condition where the stomach empties slowly). It helps researchers understand how this condition affects people over time.
Boston, MassachusettsAges 8–25 - NCT05982795Recruiting
How CF modulators affect lung bacteria
This study looks at how highly effective CF modulator therapies change the bacteria living in the lungs of people with cystic fibrosis. Understanding these changes may help improve future treatments.
Lebanon, New HampshireAges 18–99
Common questions
- How many digestive system clinical trials are recruiting?
- Clin2 is tracking 7,890 recruiting gastroenterology studies from the U.S. registry right now, out of 12,399 we cover in this area in total.
- What does “Digestive system” cover here?
- Conditions of the stomach, intestines, liver, and the rest of the digestive tract. We group each study into digestive system based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a digestive system trial near me?
- Use the search to filter digestive system studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.